COSTA MESA, Calif., Jan. 13, 2015 /PRNewswire-iReach/ -- WCCT Global (WCCTG), a rapidly growing Full Service CRO that is headquartered in Southern California will be in attendance at the 33rd JP Morgan Annual Healthcare Conference. Kenneth Kim, MD, WCCTG CEO will be present. The full service CRO is continually adding new services to help sponsors develop their novel therapeutic compounds. During 2014, WCCTG has acquired the A Cal H1N1 2009 virus, thus enabling them to offer vaccine and anti-viral influenza challenge, proof of concept trials. Another area of innovation is what WCCT Global is doing in the patient recruitment arena with the build of specialized tools to track patients and assist sponsors with analytics. All these services have been created to further expand what is possible form a CRO. Many of the top innovators in clinical research will be in attendance at this conference. Therefore, WCCT Global is looking forward to sharing its new CRO capabilities at this conference. An example of WCCT Global's innovative approach to research is shown through a recent clinical trial where 8 Phase I sites were enlisted to enroll 300 patients over a short period of time. Through these innovative recruitment tactics and past experience in this area, WCCTG was able to be the top enroller with more than twice the amount of patients than the next closest enrolling site. The 33rd Annual Healthcare Conference will be a great way to start the New Year by showcasing these innovations.
Photo - http://photos.prnewswire.com/prnh/20150112/168669LOGO
WCCT Global's Chief Executive Officer Dr. Kenneth Kim stated, "I am pleased to be in attendance at the 33rd JP Morgan Healthcare Conference and interact with many of today's leaders in healthcare and research. WCCT Global is continuously in search for strategic partnerships to further demonstrate what is capable through clinical research."
More Information about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If you would like to request more informaiton about WCCT Global, CLICK HERE.
Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
